Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
Latest Information Update: 22 Oct 2024
At a glance
- Drugs Tisagenlecleucel (Primary) ; Blinatumomab; Inotuzumab ozogamicin
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 30 Sep 2024 Planned End Date changed from 30 Aug 2024 to 30 Aug 2025.
- 30 Sep 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2025.
- 30 Sep 2024 Status changed from not yet recruiting to recruiting.